Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Sep-Oct;4(5):325-31.
doi: 10.1111/j.1524-6175.2002.01051.x.

Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements

Joel M Neutel  1 , William J Elliott, Joseph L Izzo, Chao L Chen, Harvey N Masonson
Affiliations
Clinical Trial

Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements

Joel M Neutel et al. J Clin Hypertens (Greenwich). 2002 Sep-Oct.

Abstract

Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20, or 80 mg olmesartan medoxomil q.d.; or 2.5, 10, or 40 mg olmesartan medoxomil b.i.d. Ambulatory and cuff blood pressure were measured prior to and after 8 weeks of treatment. Treatment with olmesartan medoxomil resulted in a significant placebo-adjusted reduction of mean 24-hour ambulatory diastolic blood pressure of 9.6 mm Hg, 12.2 mm Hg, and 10.6 mm Hg in the 5-, 20-, and 80-mg q.d. groups, respectively. Corresponding reductions in mean ambulatory systolic blood pressure were 14.5 mm Hg, 16.5 mm Hg, and 15.4 mm Hg. Similar reductions of diastolic and systolic blood pressure were seen with b.i.d. dosing. The diastolic trough-to-peak ratios of the q.d. doses of olmesartan medoxomil ranged from 57%-70%, indicating 24-hour effectiveness. The safety profile of olmesartan medoxomil was similar to that of placebo. Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean fitted values of 24‐hour ambulatory diastolic blood pressure (DBP) and ambulatory systolic blood pressure (SBP), as determined by Fourier analysis at baseline and after 8 weeks of treatment with 20 mg olmesartan medoxomil q.d. (n=41)
Figure 2
Figure 2
Least‐squares mean change in ambulatory diastolic blood pressure (DBP) in intent‐to‐treat patients receiving placebo (PL) or olmesartan medoxomil. All values are means±SD. The total daily dose of olmesartan medoxomil was given q.d. (filled bar) or b.i.d. (open bar). *Significant (p<0.0001) difference from placebo
Figure 3
Figure 3
Least‐squares mean change in cuff diastolic blood pressure (DBP) in intent‐to‐treat patients receiving placebo (PL) or olmesartan medoxomil. All values are means±SD. The total daily dose of olmesartan medoxomil was given q.d. (filled bar) or b.i.d. (open bar). *Significant (p<0.0001) difference from placebo
See this image and copyright information in PMC

References

    1. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637–645. - PubMed
    1. Yanagisawa H, Amemiya Y, Kanazaki T, et al. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure—activity relationships of imidazole‐5‐carboxyliv acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4‐posotion and their related compounds. J Med Chem. 1996;39:323–338. - PubMed
    1. Anonymous . Olmesartan medoxomil. Drugs Future. 1997;22:1205–1209.
    1. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of olmesartan medoxomil, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285:181–188. - PubMed
    1. Püchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of olmesartan medoxomil, a novel angiotensin II antagonist, in salt‐restricted hypertensive patients. J Hypertens. 1997;15:1809–1812. - PubMed